Evaluation of the efficacy of 2',3'-dideoxycytidine against adenovirus infection in a mouse pneumonia model.
The antiviral activity of 2',3'-dideoxycytidine (ddC) has been investigated in a mouse pneumonia model. Consolidation of lung, histopathological changes, DNA synthesis as well as levels of TNFalpha were assayed. In this in vivo model, the oral administration of ddC twice daily over 4 days, displayed an inhibitory effect. The drug significantly reduced histopathologic responses. Analysis indicated that under treatment pulmonary lesions were less severe than those of untreated controls. These data confirm the in vitro activity of ddC against adenovirus. Thus, ddC represents a potential therapeutic approach for inhibiting adenovirus infection and may offer promise as an anti-adenovirus agent for immunocompromised patients in whom serious adenovirus infection may prove fatal.
Mentel
R
R
Friedrich-Loeffler-Institut für Medizinische Mikrobiologie der Ernst-Moritz-Arndt-Universität, Martin-Luther-Str.6. D-17489, Greifswald, Germany.
Wegner
U
U
D000257:Adenoviridae Infections / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000284:Administration, Oral; D000818:Animals; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D008168:Lung / Q000378:metabolism / Q000473:pathology / Q000821:virology; D017921:Mastadenovirus / Q000187:drug effects* / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D011024:Pneumonia, Viral / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016133:Polymerase Chain Reaction; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D016047:Zalcitabine / Q000008:administration & dosage / Q000627:therapeutic use*
D004279:DNA, Viral; D014409:Tumor Necrosis Factor-alpha; D016047:Zalcitabine